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ABBREVIATIONS 
ABMR          :             Antibody Mediated Rejection 
ACR    :      Acute cellular rejection 
ATN              :             Acute Tubular Necrosis 
CAN              :             Chronic Allograft Nephropathy 
CCTT            :             Cooperative Clinical Trials In Transplantation 
CIT               :              Cold Ischaemic Time 
CKD              :             Chronic kidney disease 
CNI               :              Calcineurin Inhibitor 
DGF              :              Delayed graft function 
ESRD           :               End Stage Renal Disease 
FSGS            :              Focal Segmental Glomerulosclerosis 
IFTA             :               Interstitial Fibrosis and Tubular Atrophy 
NODAT        :               New Onset Diabetes After Transplantation 
RRT              :               Renal replacement therapy 
TCMR           :               T Cell Mediated Rejection 
TMA              :               Thrombotic Microangiopathy 
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                         INTRODUCTION 
Peter Wright in his brainy quote,  
 ‘I had been living with dialysis for three years or so, and the new 
kidney felt like a reprieve, a new gift of life. I felt alive again and I guess 
that has had an effect on my use of colour.’ 
Hence a small transplant makes a great difference for many of the 
young transplant recipients. 
The renal transplantation represents a major step in fighting against 
kidney disease. Although transplantation is by no means a cure for kidney 
failure, it is by far the best treatment method available to us at this time...  
By increasing the number of effective kidney transplants we help in 
extending the gift of life for many poor recipients. 
Studies have proved that renal transplantation is distinctly superior 
and is associated with reduced mortality and morbidity compared to 
hemodialysis or peritoneal dialysis. Due to shortage of organs and 
prolonged period to get deceased kidneys prevention of re transplant is 
gaining more importance. To improve the graft survival identifying the 
etiology and pathology of graft dysfunction or loss is most essential 
thereby effective measures can be taken to prevent the graft loss and 
prolong the survival of the recipient. 
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AIMS AND OBJECTIVES 
1. To study the clinico pathological spectrum of graft 
dysfunction in renal transplant recipients in a tertiary care 
centre. 
2. To analyse the outcome based on the histopathology 
findings.  
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REVIEW OF LITERATURE 
Chronic Kidney disease forms an emerging worldwide health 
problem. According to WHO, Chronic Kidney Disease is the 12
th 
leading 
cause of death. In India, Diabetes and Hypertension were the most 
common cause of CKD, accounting for 28.5% and 16.2% respectively.  
Renal transplantation is the best form of Renal Replacement 
Therapy in terms of quality of life and cost effectiveness 
[1]
. Hence a 
successful renal transplantation provides the finest hope for the majority 
of patients with CKD. First renal transplant in India was done on 2
nd
 
February 1971 at CMC Vellore. Around 3500 transplants are being done 
in India every year of which 95% are living donors. Living donors could 
be either genetically related or unrelated. Tamilnadu Cadaver Transplant 
programme remains a pioneer in renal transplantation for other states to 
emulate, which substantially reduced the commercialisation of renal 
transplantation. In Tamilnadu, first renal transplant in State run hospital 
was done in 1981 at Government Royapettah Hospital by Prof. 
Dr.Muthusethupathi. The premier institute of the State, Rajiv Gandhi 
Government General Hospital has done more than 1000 renal transplants 
including 100 deceased donor transplants. Nearly 70 renal transplants are 
being done at RGGH every year, of which one third of them were 
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deceased donor. In developing countries infections account for at least 
50% of the death of the patients than graft rejections or death due to 
cardiovascular disease.  
The common causes of chronic kidney disease leading to renal 
transplant include Diabetes, Hypertension, Chronic glomerulonephritis, 
polycystic kidney disease etc
 [2]
. Advances in understanding of immune 
system, molecular genetics and novel immunosuppressants has improved 
the graft  and patient survival to 95% and 90% respectively at 1 year, 
87% and 80% at 5 years. The frequent cause of death in renal transplant 
recipients with functioning graft includes infection, cardiovascular 
disease and malignancy. 
Rejection forms an important cause for decrease in graft survival. 
Rejection is defined as 
An immune response in a recipient against alloantigen of a 
donor graft which is genetically different from the recipient and unless 
controlled will destroy the graft.  
In the early 1960’s immunosuppressant agent included only 
Azathioprine and steroids which resulted in frequent acute rejection 
episodes in transplant recipients. But now due to advent use of potent 
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calcineurin inhibitors in 1980 and improved immunological matching 
system between donor and recipients, acute rejection episodes has been 
decreased. But the intensity of the episodes appeared more severe than 
before and the 5 year graft survival rates remain unaltered 
[3]
.The standard 
triple immunosuppression protocol followed is Calcineurin inhibitors 
along with steroids and mycophenolate mofetil or Azathioprine. The 
drugs are tapered in initial 3-6 months to baseline maintenance levels. 
Therefore the outcome of graft depends on the major factors like source 
of the graft, histocompatability between donor and recipient and the type 
of immunosuppression followed. Other minor factors include episodes of 
acute rejection, presensitisation, delayed graft function [DGF], age of 
donor and recipient and centre where the transplantation is being done. 
DGF is an adverse complication resulting in increased risk of acute 
rejection
[4]
 .Factors no longer considered to be the cause are blood group, 
time on dialysis, etc. 
Though the elevation in serum creatinine is indicative of rejection 
episode, subclinical rejection is evident only by renal biopsy which forms 
the gold standard in the diagnosis of rejection episode.
[5] 
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RENAL BIOPSY PROCEDURE: 
The renal biopsies in the current era are done under the guidance of 
ultrasound with a renal biopsy gun using 16 – 18 G needle and is the 
ideally safest procedure 
[6]
. The patient is put in supine position (unlike 
regular renal biopsy procedure where patient is put in prone position) and 
the biopsy is taken from the allograft kidney which is usually placed in 
right iliac fossa under aseptic precautions. The complications include 
hematuria, ureteral obstruction by clots, hemorrhage, shock, and 
arteriovenous fistula. But on follow up usually 75% of fistulas close 
spontaneously without requiring any essential intervention. 
[7] 
Generally two biopsy cores are taken and divided for light 
microscopy, immunofluorescence and electron microscopy. The biopsies 
are sent in two containers one with 10% neutral buffered formalin and 
other containing Michel’s medium. 
As per Banff ’97 update  the criteria stating the adequacy of 
specimen is  two cores of tissue with cortex having more than or equal to 
10 glomeruli and at least two arteries with a section thickness of 3-4 
micron metre
[8]. 
The sensitivity of renal biopsies depends on the size, 
number and content of  cores, with a single core the sensitivity is 90%. 
The tissue is processed for light microscopy as for routine paraffin 
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embedding and sections are cut at 3-4 microns using rotary microtome. 
All sections need to be stained for Haematoxylin and Eosin, Periodic 
Acid Schiff and for selected cases with Masson’s Trichrome and 
Methanamine Silver stains. Immunofluorescence for C4d is carried out 
for all cases using the routine protocol. Sub capsular biopsies usually 
show inflammation and fibrosis within 1-2mm of capsule due to 
transplantation procedure and hence deep biopsies are advised. Wedge 
biopsy is not representative as it includes mainly outer cortex and the 
sclerosis and fibrosis due to vascular disease is severe. Intimal fibrosis 
affects arcuate and larger arteries than interlobular arteries and hence is 
underrepresented in wedge biopsy.
[9]     
 
RENAL ALLOGRAFT DYSFUNCTION:
 
After an allograft is transplanted, a variety of donor and recipient 
factors determines the long term outcome of the graft. 
Donor risk factors: 
 Deceased donor [donation after brain death] 
 Age more than 60 years 
 Co morbid conditions[ HTN,DM] 
 Female sex [small renal mass] 
 Prolonged cold ischemic time 
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Recipient risk factors: 
 Age & Size mismatch 
 HLA mismatch 
 Obesity 
 Co morbid status 
 Smoking  
 Proteinuria 
 Poor drug compliance 
CAUSES OF GRAFT DYSFUNCTION: 
Number of immunological and non immunological factors play a 
major role in functioning of graft and chance of graft loss.
[10]   
 
Immune Mediated: 
 Antibody mediated rejection 
 Acute cellular rejection 
 Non compliance with treatment 
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Non immune Mediated: 
 Glomerular disease [recurrent or de novo] 
 Infections [ UTI,CMV,Polyoma virus] 
 Calcineurin inhibitor nephrotoxicity 
 Transplant ureteric obstruction 
 Transplant artery stenosis 
 Graft vessel thrombosis 
BANFF SCHEMA FOR RENAL ALLOGRAFT REJECTION – 
PASSED MILESTONES 
With the intention to develop a grading system which is easy to 
learn, easy to use, reproducible and has defined clinical end points, the 
Banff schema was introduced. The aim of this system is to have a better 
understanding between clinicians, pathologists and researchers in or 
between transplant centres, to be able to compare therapeutic strategies 
and their outcome, to facilitate multicentric trials, to promote further 
research looking for different histological patterns.  
The Banff criteria helps in homogeny of renal allograft biopsy 
evaluation , acts as a channel to therapy and establishes an objective point 
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of view for clinical trials and thereby reducing the inter and intra observer 
variability in interpretation .  
In 1991, the first Banff conference was held in Banff, Canada 
under the leadership of Kim Solez,Philip Halloran, Loraine and the 
details of the meeting were published in Kidney International in 1993
[11]
. 
According to which specimen adequacy was taken as more than seven 
glomeruli with at least one artery and biopsies were classified into the 
following categories- normal, hyper acute rejection, borderline rejection, 
chronic allograft nephropathy, and others i.e., changes not due to 
rejection. 
In 1995, the scoring for chronic allograft damage index was 
brought into use. In 1997, the Cooperative Clinical Trials in 
Transplantation (CCTT) was integrated with the Banff scheme in the 4
th
 
conference and in 1999; the second paper was published
 [12]
. In its 6
th
 
conference on 2001, the classification of antibody mediated rejection was 
introduced
 [13]
. In 2003, updates on schemes of allograft rejection, in its 
7
th
 Banff conference on Aberdeen, Scotland where chronic allograft 
nephropathy, genomics of rejection, antibody mediated rejection/C4d 
were put forth
 [14]
. In 2005, 8
th
 Banff conference was held in Edmonton, 
Canada, where the outcomes included elimination of CAN, identification 
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of entity of chronic antibody mediated rejection
 [15]
. In 2007, the 9
th
 Banff 
conference was held in Lacoruna, Spain. Updates included i) grading of 
peritubular capillaritis  was included ii) scoring of C4d  iii) interpretation 
of C4d scoring without morphological evidence of C4d deposition and 
applying of this criteria to zero time and protocol biopsies and 
introducing the scoring system for the inflammatory cells in the 
interstitium(ti score)
[16]
. In 2009, the conference was held in Banff, 
Alberta, Canada. Here genomics, proteonomics approaches to rejection 
diagnosis, noninvasive surrogate markers of rejection, role of endothelial 
cell in rejection and phenotyping of late kidney transplant detonation 
were discussed. The 11
th   
conference on Banff criteria was held in Paris, 
France in 2011 and the results are yet to be published.  
Banff 2007 classification of    Renal allograft Pathology (Banff 97 
diagnostic categories for renal allograft biopsies - Banff’07 
update.)
[16]. 
1. Normal 
2. Antibody-mediated changes (may occur with categories 3, 4 and 
5 and 6) Anti donor antibodies and C4d or allograft pathology 
documentation 
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C4d deposition without morphologic evidence of active rejection 
C4d+, presence of circulating anti donor antibodies, no signs of 
acute or chronic TCMR or ABMR. 
Acute antibody-mediated rejection 
C4d+, presence of circulating antidonor antibodies, morphologic 
evidence of acute tissue injury, such as (Type/Grade): 
I. ATN-like minimal inflammation  
II. Capillary and or glomerular inflammation (ptc/g>0) and/or 
thromboses 
III. ‘Transmural’ arteritis and/or arterial fibrinoid change and necrosis 
of medial smooth muscle cells with accompanying lymphocytic 
inflammation (v3) 
Chronic active antibody-mediated rejection 
C4d+, presence of circulating antidonor antibodies, morphologic 
evidence of chronic tissue injury, such as glomerular double contours 
and/or peritubular capillary basement membrane multilayering and/or 
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interstitial fibrosis/tubular atrophy and/or fibrous intimal thickening in 
arteries 
3.  Borderline changes: ‘Suspicious’ for acute T-cell-mediated 
rejection.  
This category is applied when there is no intimal arteritis, but there 
is evidence tubulitis in some foci (t1, t2 or t3) with minor inflammatory 
cell infiltrate in the interstitium (i0 or i1) or interstitial infiltration (i2, i3) 
with mild (t1) tubulitis 
4. T-cell-mediated rejection (TCMR, may coincide with categories 
2, 5 and 6) 
Acute T-cell-mediated rejection (Type/Grade) 
IA. Significant interstitial infiltration (>25% of parenchyma 
affected, i2 or i3) and foci of moderate tubulitis (t2)  
IB. Significant interstitial infiltration (>25% of parenchyma 
affected, i2 or i3) and foci of severe tubulitis (t3) 
IIA.Mild-to-moderate intimal arteritis (v1) 
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IIB. Severe  intimal  arteritis  comprising >25% of the luminal  
area (v2). 
III. Transmural’ arteritis and/or arterial fibrinoid change and 
necrosis of medial smooth muscle cells with accompanying lymphocytic 
inflammation (v3).  
Chronic active T-cell-mediated rejection 
‘Chronic allograft arteriopathy’ (arterial intimal fibrosis with 
mononuclear cell infiltration, formation of neo-intima). 
5. Interstitial fibrosis and tubular atrophy, no evidence of any 
specific etiology (may include nonspecific vascular and glomerular 
sclerosis). 
Grade  
I. Mild interstitial fibrosis and tubular atrophy (<25% of 
cortical area) 
II. Moderate interstitial fibrosis and tubular atrophy (26–50% of 
cortical area) 
III. Severe interstitial fibrosis and tubular atrophy/ loss (>50% of 
cortical area) 
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6. Others:  
Changes not considered to be due to rejection—acute and/or 
chronic; may include isolated g, cg or cv lesions and coincide with 
categories 2, 3, 4 and 5) 
Banff ’97 criteria   set a footprint in the field of renal transplant 
pathology. It has incorporated both the first Banff schema and CCTT 
modifications
 [12]
. The changes included are  
i. Adequacy of specimen was changed from 7 glomeruli to 10 
glomeruli and one artery into two. 
ii. The term hyper acute rejection under category 2 was replaced 
by antibody mediated rejection. 
iii. Under category 3, active/ acute rejection, grades were changed 
to type I, II and III by giving importance to vasculitis. 
 In Banff’ 97 update, value of C4d staining in the peritubular 
capillaries was well thought-out as an  indicator of antibody mediated  
rejection, pathological classification of antibody mediated  was outlined, 
the term acute rejection was renamed as acute/ active cellular rejection
[13]
. 
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CATEGORIES IN BANFF: 
1. NORMAL 
2. ANTIBODY MEDIATED REJECTION : 
This is classified into acute and chronic active antibody mediated 
rejection. HLA molecules, endothelial cell antigens, ABO blood group 
antigens seen on endothelial cells and red blood cells are the antibodies 
that mediate the rejection process.  Usually, in our set up transplantation 
is being done between ABO compatible donor and recipients. But recent 
studies show that even ABO mismatched kidneys have been effectively 
transplanted by using experimental protocols that require perioperative 
elimination of antibodies from recipient by means of plasmapheresis or 
immunoadsorption. After removal the antibodies to blood group antigens 
elevate to pretreatment levels, stick to microvasculature, trigger the 
complement system, but in general they do not damage the endothelium. 
This is attributed to phenomenon called “accommodation” within the 
kidney, but the mechanism responsible for this process is not known
 [17]
. 
But damage to the graft by anti HLA antibodies is insidious and 
accommodation is unusual. 
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Acute antibody mediated rejection: 
It is also called acute humoral rejection, occurs as a result of  
antidonor antibodies against HLA and blood group antigens. The 
rejection can occur immediately on the table or even weeks to months 
later. Clinically patient presents with anuria/oliguria. The main picture is  
inflammation due to previous exposure to relavent antigen by means 
blood transfusion, pregnancy and previous transplant, which swiftly 
generates elevated titres of complement fixing antibodies. The major 
targets are the MHC antigens displayed by the endothelium of donor 
peritubular and glomerular capillaries.            
Grossly the kidney becomes cyanotic, flabby and soft, and then it 
swells due to interstitial hemorrhage and cortical necrosis. The 
pathological findings are acute tubular necrosis, neutrophils in peritubular 
capillaries, thrombi and fibrinoid necrosis along with C4d deposition.  
Acute antibody mediated rejection types include: 
Type I: C4d +, ATN like minimal inflammation 
Type II: C4d+, capillary margination and or thrombosis 
Type III: C4d +, transmural arteritis 
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 Chronic humoral rejection: 
This is otherwise referred to as chronic active antibody mediated 
rejection. 
The criteria includes C4d positivity along with the following 
histopathological findings like interstitial fibrosis and tubular atrophy 
associated with transplant glomerulopathy identified as glomerular 
basement membrane duplication, increased mesangial matrix, increased 
amount of endothelial cytoplasm, loss of fenestrations and transplant  
capillariopathy  identified by loss of peritubular capillaries resulting in 
decreased capillary density, multilamination of peritubular capillary  
basement membranes and transplant arteriopathy identified by arterial 
intimal fibrosis with intimal monocyte infiltration and serology shows 
antidonor HLA or other endothelial antigens .    
MECHANISM OF C4d DEPOSITION: 
The AMR is caused by antibodies which are directed against HLA 
class I-II antigens. Antibodies against donor alloantigen target the 
capillary endothelium and not the arterial endothelium, by fixing with the 
complement, ensuing in tissue injury and coagulation. Antibodies can 
activate complement by means of classical pathway by binding C1 and/or 
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by binding to the mannose-binding lectin pathway. Upon activation, C3 
splits into C3a and C3b. C3b amplifies the alternative pathway, but the 
chemo attractant C3a and C5a recruit macrophages along with 
neutrophils, leading to endothelial injury. The end result is that arteries 
and basement membranes gets remodelled, causing permanent and 
irreversible anatomical lesions that enduringly compromise graft 
function. The role of complement activation is established by the copious 
existence of C4d in peritubular capillaries which is the terminal 
component of the complement cascade that persists in graft tissue. This 
finding is considered a reliable marker of humoral rejection and has been 
incorporated into Banff classification   
C4d staining of peritubular capillaries was graded as follows: 
C4d 0 – negative 
C4d 1 – minimal (1-10 % ) 
C4d 2 – focal (10 – 50 %) 
C4d 3 – diffuse (> 50 %)  
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Qualitative criteria for transplant glomerulopathy: 
cg0: glomerulopathy is absent, evidence of double contours in 
<10% of the peripheral capillary loops in most severely affected 
glomerulus   
cg1: evidence of double contours up to 25% of peripheral capillary 
loops in most of the affected nonsclerotic glomeruli  
cg2: evidence of double contours in 26 to 50% of the peripheral 
capillary loops in most of the nonsclerotic glomeruli   
cg3: evidence of double contours in more than 50% of peripheral 
capillary loops in most affected nonsclerotic glomeruli 
Qualitative criteria for interstitial fibrosis: 
ci0: Interstitial fibrosis seen up to 5% of cortical area   
ci1: Mild - Interstitial fibrosis tissue seen in 6 to 25% of cortical 
area  
ci2: Moderate - interstitial fibrosis seen in 26 to 50% of cortical 
area   
ci3: Severe - interstitial fibrosis affecting >50% of cortical area   
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Quantitative Criteria for Tubular Atrophy: 
ct0: absence of tubular atrophy   
ct1: Presence of tubular atrophy in 25% of the area of cortical 
tubules  
ct2: Presence of tubular atrophy in 26 to 50% of the area of cortical 
tubules   
ct3: Presence of tubular atrophy in >50% of the area of cortical 
tubules  
Quantitative Criteria for Fibrous Intimal Thickening ("cv")  
cv0:  chronic vascular changes absent 
cv1: Vascular narrowing seen up to 25% luminal area by means of 
fibrointimal thickening of arteries with or without breach of the 
internal elastic lamina or evidence of foam cells or occasional 
mononuclear cells  
cv2: Increased severity of above described changes involving 26 to 
50% narrowing of vascular luminal area 
cv3: Severe vascular changes involving >50% narrowing of 
vascular luminal area  
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Quantitative Criteria for Mesangial Matrix Increase (“mm”) 
mm0: No increase in mesangial matrix  
mm1: 1 – 25% of glomeruli show increase in mesangial matrix 
mm2: 26 – 50% of glomeruli show increase in mesangial matrix 
mm3: >50% of glomeruli show increase in mesangial matrix 
Quantitative Criteria for Arteriolar Hyaline Thickening ("ah")  
ah0: absence of PAS-positive hyaline thickening  
ah1: evidence of mild-to-moderate PAS-positive hyaline 
thickening involving at least one arteriole  
ah2: evidence of moderate-to-severe PAS-positive hyaline 
thickening involving more than one arteriole  
ah3: evidence of severe PAS-positive hyaline thickening involving 
many arterioles  
Antibody mediated rejection can occur alone or along with T- cell 
mediated rejection. 
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         Early identification and apt treatment is needed for the damaging 
grafts by rejection. Treatment options include immunoadsorption, 
plasmapheresis, high pulse doses of steroids, intravenous 
immunoglobulins. Additional treatment modalities include 
antilymphocyte antibodies when there is admixed  T – cell mediated 
rejection.
[18]  
These are beneficial when given as prophylaxis to most 
sensitized or ABO-incompatible recipients
[19]
. When potentially 
detrimental antibodies are detected prior to transplantation, effective 
search for an alternative donor or an aggressive approach of management 
after transplantation must be carried out to prolong the survival of the 
recipient.   
Category III BORDERLINE CHANGES:  
This is characterised by mononuclear cell infiltration in less than 
25% of parenchyma or a foci of tubulitis (1 to 4 mononuclear cells per 
tubular cross sectional area). The treatment of borderline category 
remains not much essential. 
Category IV T- CELL MEDIATED REJECTION:   
This is the common form of acute allograft rejection. The rejection 
is initiated when the antigens of the donor are presented to the T-
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lymphocytes of the recipient by means of antigen- presenting cells. 
Immature dendritic cells present in the graft take the donor antigens to the 
recipient’s draining lymphnodes and spleen during their path they mature 
into antigen presenting cells
 [20]
. The antigen presenting dendritic cells of 
the recipient are also involved by circulation through the graft and these 
APC’s reside to the lymphoid organs thereby activating the T-cells of the 
recipient. These T- cells separate into various subgroups come back to 
graft and plays an important role in destroying the graft.    
The MHC codes the HLA system and mismatch in the HLA 
antigens between the donor and the recipient increases the risk of 
rejection. Grafts from HLA identical siblings have an increased survival 
rate than unrelated donors. There requires hardly any amino acid 
differences in the peptide binding site of MHC to incite the rejection 
reaction. 
T-cells mediated injury of the allograft is by their direct  contact 
with the epithelial cells of the renal tubules and by  the effects of the  
cytokine release. They have an indirect action by activating the 
inflammatory cells or cells of the vascular endothelium. Perforin of the 
CD8 T-cells causes cell membrane damage and granzymes A and B cause 
caspases mediated apoptosis in the cells. The Fas ligand present on the T-
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cells activates the Fas receptor on the cells of the graft and lead to 
caspases mediated apoptosis. 
CD8 T cells will attack the graft cells by means of expressing 
minor MHC antigens and also secrete TNF-α and TNF – β. These bind to 
the receptors of TNF present on the endothelial cells and tubular 
epithelial cells and leads to apoptosis. In grafts with acute rejection, the 
T-lymphocytes infiltrate and proliferate in the interstitial space where 
they invade the renal tubules and causes tubulitis. CD8 lymphocytes 
invading the allograft with immunologic specificity pass through renal 
tubular basement membrane, there they proliferate and cause apoptosis of 
the tubular epithelial cells. Some of the sub lethally injured tubular 
epithelial cells gets transformed from their original epithelial phenotype 
into primitive mesenchymal myofibroblasts initiating the   fibrosis of 
interstitium. Tubular epithelial cell necrosis and rupture of the basement 
membrane ultimately leads to leakage of urine, graft dysfunction and 
tubular atrophy .  This is divided into acute and chronic forms. 
Qualitative criteria for tubulitis scoring: 
t 0 – absence of mononuclear cells in tubules  
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t 1 – foci of  1 to 4 cells per  tubular cross sectional area per 10 
tubular cells 
t2 – foci of 5 to 10 cells per tubular cross sectional area 
t3- foci of  >10 cells per  tubular cross section or t2 tubulitis with  
i2/i3 with  at least two areas showing destruction of tubular 
basement membrane 
Qualitative criteria for mononuclear interstitial inflammation: 
i 0 – absent or insignificant interstitial inflammation  
i 1 – 10-25 % of parenchyma shows presence of inflamed cells 
i2 – inflammation of 26 – 50 % of parenchyma 
i3 - >50 % of parenchyma shows inflammation. 
Qualitatative criteria for intimal arteritis: 
v 0 – arteritis absent 
v 1 – presence of mild to moderate intimal arteritis in at least one 
arterial cross section 
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v 2 – severe intimal arteritis showing loss of  at least 25% luminal 
area  in at least one arterial cross section .  
v 3 –  fibrinoid change in the arteries and or transmural arteritis 
with smooth muscle necrosis of media with lymphocytic 
infiltration . 
Qualitative criteria for glomerulitis: 
g 0 –  glomerulitis absent 
g 1 – glomerulitis seen in more than 25% of glomeruli 
g 2 – segmental/ global glomerulitis seen in about 25 – 75% of 
glomeruli.  
Acute T cell mediated rejection : 
This has recently become a well defined category in Banff 2007 
update.  This occurs after 5-6 days of transplant clinically presenting as 
frequent oliguria. This time is taken for the antigen presenting cells to 
present the alloantigens in spleen and lymphnodes. There is interstitial 
infiltrate mainly T-lymphocytes and macrophages, along with edema and 
occasional hemorrhage. There is tubulitis. Endarteritis is seen in type II 
rejection and is characterised by infiltration of mononuclear cells under 
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the vascular endothelium of arteries and arterioles. Normally these cells 
express HLA class I antigen but during rejection it expresses HLA-DR, 
ICAM-I and VCAM-1.
 [21] 
           Glomerular lesions are very uncommon. The endothelial cells may 
be enlarged, hyper cellular with infiltration by mononuclear cells. Other 
cells seen may be eosinophils but it is associated with high grades of 
rejection and carries worst prognosis. Presence of plasma cells, CD20+ B 
cells in interstitium also carries poor prognosis. 
Acute T- cell mediated rejection is classified into three types. 
I A- i2 /i3 + t2 
IB – i2/i3 + t3 
II A- v 1 
II B – v2 
III –presence of transmural arteritis and or fibrinoid change in the 
arteries. Medial smooth muscle cell necrosis with accompanying 
lymphocytic infiltration. 
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          The mainstay of treatment for acute cell mediated rejection is bolus 
steroids for three days followed by immunosuppressants. 
Some of the pathological features of acute rejection carry 
prognostic significance either as a single component or in combination. 
The main predictor is the arterial lesions. Endarteritis in type II rejection 
carries an adverse prognosis when compared to tubulointerstitial rejection 
with arterial involvement. Patients with type I rejection has 1 year 
survival rate of 90% when compared to type II rejection where the 
survival rate is 75%.   Infarction an ominous finding in graft biopsy is 
associated with decrease in graft survival rate. 
[22]
 
Chronic active T cell mediated rejection: 
The distinctive feature is chronic allograft arteriopathy 
characterized by intimal fibrosis of arteries with mononuclear cell 
infiltration and formation of  the  neointima.  
CATEGORY 5 INTERSTITIAL FIBROSIS AND TUBULAR 
ATROPHY: 
Now this has replaced the term CAN in Banff 2005 as CAN was 
thought to include other entities like chronic rejection, cyclosporine 
toxicity, hypertensive changes and chronic infection. The diagnosis of 
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IFTA is given if other causes of chronic histopathological changes in 
allograft fail. 
This has been graded into mild, moderate and severe based on the 
intensity of changes seen in the interstitium. 
Mild: changes in < 25% of the cortical area  
Moderate: changes involving 26 – 50% of the cortical area 
Severe:changes seen in  > 50% of  the cortical area 
CATEGORY 6 OTHERS: 
This includes the causes and changes which are not considered due 
to rejection. The causes include acute tubular necrosis, acute interstitial 
nephritis, cyclosporine toxicity, papillary necrosis, viral infection, 
obstruction/ reflux, focal interstitial inflammation without tubulitis, renal 
vascular changes, venulitis, denovo glomerulonephritis, and recurrent 
diseases like FSGS, DM, and HUS etc. 
Acute Calcineurin Inhibitor Nephrotoxicity: 
The Calcineurin Inhibitors, particularly in high doses, leads to 
acute irreversible increase in glomerular filtration rate by 
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vasoconstriction, mainly involving afferent arteriole. This is manifested 
clinically by acute reversible increase in plasma creatinine based on the 
dosage. Histologically the changes include isometric vacuolization of 
tubules, chronic cases show hyaline thickening of arterioles and striped 
fibrosis
 [13]
. This condition is reversible with reduction of the dosage of 
CNIs and close follows up with cyclosporine levels.  
Chronic Calcineurin Inhibitor Toxicity: 
This is characterised by interstitial fibrosis and tubular atrophy 
[especially striped fibrosis], arteriolar hyalinosis of the media, fibrosis of 
glomerular capsule, global glomerulosclerois and tubular 
microcalicfication. 
Acute Thrombotic Microangiopathy: 
This is a rare yet a serious complication 
[23]
 and the causes include 
CNIs, acute AMR, viral infections like cytomegalovirus and recurrence 
of the primary disease. The existence of hepatitis C and anticardiolipin 
antibodies will increase the risk.
[24]
 This often  presents in the post 
transplant period. The typical laboratory findings include elevation in 
plasma creatinine and lactate dehydrogenase levels, decrease in platelet 
count, decrease in haemoglobin levels, schistocytosis and low 
haptoglobulin levels. In severe cases the long term prognosis of the 
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patients is poor. Early diagnosis is essential to salvage renal function. 
There are no proved trials  of therapy for TMA  after  transplant.  
Acute Allergic Interstitial Nephritis: 
The demarcation between acute allergic interstitial nephritis and 
acute cellular rejection remains very difficult. Infact, the pathogenesis is 
somewhat similar in both cases, involving mainly cell mediated 
immunity. Fever and rash after ingestion of a new drug will cause the 
former and both the conditions respond well to steroids. 
Recurrence of primary disease: 
This could   be early or late recurrence.  
Many renal diseases may reappear early and form a basis for acute 
allograft dysfunction. Among them the most commonest include primary 
focal segmental glomerulosclerosis, antiglomerular basement membrane 
disease etc,. The frequency of late recurrence is difficult to estimate, the 
novel cause of ESRD is often not known as transplant kidney biopsies are 
not performed all the time. In one study patients who underwent 
transplantation after developing ESRD from glomerulonephritis, 
recurrence was considered the third most frequent cause of graft loss at 
10 years. The following table gives the incidence of commonly recurring 
primary disease in a graft and its risk of graft loss. 
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TABLE - 1 
RECURRENCE RATE OF NATIVE KIDNEY DISEASES 
[25] 
Disease Recurrence rate Risk of graft loss 
Ig A nephropathy 13-40% 2-15% 
FSGS 20-40% 10-20% 
Membranous 10-30% 10-15% 
MPGN 1 
MPGN 2 
20-30% 
80-100% 
15% 
60% 
SLE 5-10% 2-4% 
ANTI GBM < 5% < 2% 
D- HUS 30-60% 90 % 
 
Post renal dysfunction in the early post transplant period: 
          Though the causes of early post –transplant urologic complications 
has decreased significantly in the past 20 years, the causes must always 
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be remembered in the differential diagnosis of acute allograft 
dysfunction. The causes include  
1. Urine leak 
2. Urinary tract obstruction  
Transplant Renal Artery Stenosis: 
This can happen at any time following transplantation [2 months to 
2 years]. The incidence reported varies widely. Luminal narrowing of 
more than 70% is necessary to make the stenosis functionally significant. 
The stenosis can occur at the donor or the recipient artery or at the 
anastamotic site. The recipient iliac artery stenosis may also compromise 
to the renal arterial flow. The causes for stenosis include operative trauma 
caused to the vessels, atherosclerosis of the recipient vessels, and the 
immunological factors. Renal angiography remains the gold standard in 
diagnosis. Percutaneous transluminal angioplasty is the treatment of 
choice for more severe cases.  
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INFECTIONS CAUSING LATE ACUTE ALLOGRAFT  
DYSFUNCTION: 
Human Polyoma virus Infection: 
These are DNAviruses , the best known of which are the BK virus, 
JC virus and SV 40virus. Over the past 10 years the BK virus is 
progressively more documented as important reason of renal allograft 
dysfunction and graft loss.  
Replication  of the BK virus ,  along with shedding of  the infected 
uroepithelial cells[ decoy cells] into urine occurs in majority of the renal 
transplant recipients.
[26]
 The clinical features comprises of  acute and 
chronic allograft dysfunction  and hemorrhagic cystitis. The allograft 
dysfunction occurs primarily due to interstitial nephritis. Diagnosis by 
renal biopsy shows presence of intranuclear inclusions in the tubular 
epithelial cells by light microscopy and is confirmed by 
immunohistochemistry. The therapy for established BKvirus nephropathy 
is decreasing the dose of immunosuppression to enhance host 
mechanisms of viral clearance. 
Hepatitis C: 
The management of hepatitis C virus in renal transplant recipients 
remains unsatisfactory. The main step in treatment is to reduce the 
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immunosuppression but this increases the risk of rejection. Both MPGN 
and membranous nephropathy are commonly seen in HCV positive 
patients when compared with negative patients.  
Drug and radio contrast chemicals also form the cause for  acute 
renal transplant rejection. 
Measures to improve renal allograft survival : 
 Increased live kidney donors : both related and nonrelated 
 Efficient and eminent surgical skills during transplantation 
 Increased donation from younger and previously healthy deceased 
 donors 
 Preferential matching of younger deceased donor with younger 
 recipients 
 Zero mismatching of HLA antigens. 
 Improved organ preservation  
 Reduced cold ischaemia time 
 Nephron dosing 
 Calcineurin inhibitor sparing immunosuppression protocols 
 Control of hyperlipidemia, hypertension  
 Early diagnosis by biopsies and effective treatment. 
 48 
 
 
 
 
 
MATERIALS AND 
METHODS 
 
 
 
 
 
 49 
                MATERIALS AND METHODS 
Study place : 
Madras Medical College 
Institute of Pathology and Department of Nephrology 
Study period : 
From   July 2010 to November 2012 
Study design:     
Prospective study 
Study Population : 
Patients who underwent transplant in Madras Medical        
College and on regular follow up in the outpatient 
          Department with evidence of graft dysfunction. 
In the Department of Nephrology renal transplants are being done. 
Transplants are of live related between first degree relatives, spousal and 
cadaver transplants. 
 50 
Depending on the post transplant period the patients are followed 
up once in a week or once in two weeks.  
Raised creatinine of >25% from the baseline or increase in 0.3 – 
0.5 mg from the baseline creatinine level was considered as criteria for 
graft dysfunction. All patients with graft dysfunction were subjected to 
graft biopsy after  ruling  out other causes of graft dysfunction. 
DONOR EVALUATION: 
Live related donor: 
Only first degree relatives were selected as donors. Spousal donors 
are considered for recipients who do not have medically fit / willing first 
degree relatives. Donors more than 20 years and less than 60 years are 
selected. Donor who were hypertensive or diabetic during screening were 
rejected. Donors are evaluated by history, clinical, biochemical and 
imaging modalities. A written informed consent is obtained from the 
donor and donor guardians.  
Cadaver donors:  
Brain dead donors mostly are road traffic accident victims. Donors 
were screened for diabetes, hypertension, underlying renal disease prior 
to harvesting. They are also screened for HbsAg, anti HCV, and HIV 
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serology. Donor’s age ranged from 15 to 65 years. Donor kidneys were 
received from all hospitals in Tamilnadu.  
RECIPIENTS: 
Recipients of less than 60 years of age were selected. The cause of 
NKD is identifiable in 33 % of cases. All patients underwent viral 
screening for HBV, HCV, and HIV. At Government General Hospital, 
eight patients who were positive for HCV underwent successful renal 
transplantation. 
Donor and recipient tissue cross match was done using 
complement dependent lymphocytotoxic  method within 72 hours before 
transplant and only those with cross match 20% or less were taken up for 
surgery. HLA Cross matching was not done due to its non availability in 
our hospital. 
Preoperatively all the recipients were on regular hemodialysis in 
our hospital. Postoperatively immunosuppression is given and is followed 
up in outpatient department. During each visit the patient’s renal 
condition is assessed by the renal function tests and recipients with graft 
dysfunction were taken up and analysed with renal biopsy to assess the 
cause of renal dysfunction. 
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FIXATION AND TRANSPORT 
Generally two cores of tissue are taken and one core in formalin 
and other core is transported in Michel’s medium the composition of 
which is as follows:  
1M Potassium citrate buffer pH 7.0: 
21.0g of citric acid monohydrate (or 19.2 g anhydrous citric acid) 
is dissolved in 30 ml of hot deionized or distilled water. It is made to 
cool. Adjust the pH to 7.0 with 1 M potassium hydroxide (about 35ml). 
Dilution is made up to 100ml with more water. 
Components of washing solution:  
25ml of 1.0 M potassium citrate buffer 
50ml of 0.1 M magnesium sulphate heptahydrate 
50ml of 0.1 M N- ethyl maleimide 
Water to make 1 litre. 
Adjust to pH 7.0 with 1 M potassium hydroxide. Store in 
refrigerator.  
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Transport medium:  
55 grams of ammonium sulphate is dissolved by adding slowly 
with mechanical stirring in 100 ml of the washing solution. Adjust the pH 
to 0.9 with 1M potassium hydroxide. Specimens can be kept at room 
temperature for five days in the transport medium. Specimens which are 
received in transport media must undergo washing with three changes of 
washing solution about 10 minutes each.  
 For paraffin embedding the material was put in a container, with 
10% neutral buffered formalin. For light microscopic study the tissue is 
processed in the routine paraffin embedding method. Sections of 2 – 3 
micron are taking using rotary microtome. All sections are stained with 
Haemotoxylin – Eosin stain and PAS stain.  
SPECIAL STAINS 
For selected cases Masson’sTrichrome stain (MTS), and Silver 
Methanamine stains were supplemented.MTS were used to demonstrate 
the basement membrane thickening. PAS was used to demonstrate 
increase in mesangial matrix, mesangial cellularity, and basement 
membrane changes and to demonstrate tubular casts. 
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Procedures: 
(i) Haematoxylin and eosin staining: 
1. Sections are dewaxed and hydrate sections through graded alcohols 
to water. 
2. Staining is done with Harris Haematoxylin for 5 minutes. 
3.  Tap water wash 
4. Differentiate with 1% acid alcohol. 
5. Blueing by washing with tap water for 10-15 minutes. 
6.  Eosin 1% stain for 1 minute. 
7. Wash with tap water for 5 minutes 
8. Dehydration done  with xylol and mount in DPX 
Results: 
Microscopic features seen includes inflammatory infiltrate of 
interstitium, tubular inflammation, arteritis, and vacuolization of tubules 
and inflammation of glomeruli. 
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(ii) Periodic acid Schiff stain: 
1. Dewax and bring sections  to distilled water. 
2. Add periodic acid wait for 5 minutes 
3. Washing done with several changes of distilled water. 
4. Add Schiff’s reagent and wait for 30 minutes. 
5. Wash with tap water for 5 – 10 minutes. 
6. Counter stain with Harris Haematoxylin. Differentiation done 
with acid alcohol and blueing with tap water for 5 minutes. 
7. Wash with water. 
8. Rinse in absolute alcohol 
9. Clear in xylene and mount. 
Results: 
Basement membrane duplication 
Tubular basement membrane lamination. 
Vacuolations of tubular epithelial cells. 
Arteriolar hyalinosis. 
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IMMUNOFLUORESCENCE TECHNIQUE 
This technique is used to detect and localize antigens by means of 
fluorescent labelled antibodies through antigen antibody interaction that 
are visualised under fluorescence microscope.  
In this technique a FITC labelled antibody is used to visualize a 
cellular antigen under the fluorescence microscope. 
Sample processing 
Sample is received in the Department of Pathology.  A ‘chuck’ 
(tissue holder) is taken, the centre of which OCT embedding medium is 
placed. The specimen is transferred from the Michel’s medium into the 
centre of OCT medium. The chuck with the specimen is kept inside the 
cold cryostat at –30o C for 5 minutes, for fixation. Once the material is 
fixed in chuck, the tissue sections are made within cryostat at – 22 o C for 
3 – 4 micron thickness (Ideal 4 micron for excellent details). The section 
is mounted on a slide. At least seven individual sections (only one 
section/ slide) are submitted for IF study. The balance tissue put back in 
formalin for later use. The slides containing the sample left overnight at 
22
o
C, for fixation. After fixation, the site of tissue in the slide is 
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encircled, using dark blue pencil, for easy identification of the site on 
which the antibody solutions have to be poured. 
The Slides are marked in following order: 
IgG, IgA, IgM, C3, C1Q, C4d 
(IgG – Two slides are made as artifact uptake of IgG is high) 
STEP I: 
Slides are washed in PBS (Phosphate buffered saline) 3 times, 
rinsed and washed in 10 minutes cycle. Slides made dry. 
STEP II: 
Slides are kept in slide tray to which the appropriately marked, 
reconstituted antibodies on poured – added, in dark dust free 
environment, covered and kept for ½ hour contact time.  
STEP III: 
The same slide, after ½ hour is re – washed. Step I repeated – 3 
washes with PBS 10 minutes x 3 cycles. Slides are then allowed to dry. 
Dried slide is mounted with glycerol in BPS ( Mounting media) and the 
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cover slip placed.The slides are examined under  IF microscope, having 
mercury lamp and a blue light ( NIKON – IF microscope). 
Apart from the routine antisera, following steps are added for C4d 
staining.  
STEP IV: 
FITC labelled antibody is added and again wait for 30 – 45 
minutes.  
STEP V:  
Phosphate buffer wash. 
STEP VI: 
Dry and mount with appropriate mounting media  
Mounting media composition: 
Phosphate buffer saline: 1ml 
Glycerine- 9ml 
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RESULTS: 
Peritubular capillaries show staining of C4d due to antibody 
mediated rejection. 
Recurrent IgA nephropathy staining by IgA antibody show 
granular positivity in the mesangium. 
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INCLUSION CRITERIA 
           Renal transplant recipients who underwent transplantation at Rajiv 
Gandhi Government general hospital and on regular follow up in the 
department of Nephrology with Graft dysfunction were taken up. 
 
EXCLUSION CRITERIA 
1. Patients who were on irregular follow up during the study period  
2. Patient who developed surgery related complications.  
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METHODS 
All the renal transplant patients who were on regular follow up and 
had renal dysfunction were taken up for the study. These patients 
underwent renal biopsy and the findings were categorised using BANFF 
2007 update criteria  
The following parameters were analysed.  
Donor parameters included: 
1. Age 
2. Sex 
3. Blood group 
Recipient parameters included: 
1. Age  
2. Sex 
3. Blood group 
4. Duration of development of dysfunction  
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5. Days to reach normal creatinine 
6. Type of immunosuppression 
Biopsy findings: 
1. Antibody mediated rejection   
2. Cell mediated rejection 
3. Borderline changes 
4. Interstitial fibrosis and tubular atrophy 
5. Others 
6. C4d immunostaining 
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OBSERVATION AND RESULTS 
Totally 52 recipients with renal dysfunction from the period of  
July 2010 to November 2012 were taken up for the study.  
Patients who had surgical complications and who are on irregular 
follow up are excluded from the study. 
Graft dysfunction is defined as raise in creatinine more than 25% 
from the baseline or 0.3 to 0.5 mg raise from discharge creatinine. 
All recipients with graft dysfunction underwent biopsy if creatinine 
does not come down soon and there is no plausible cause. 
The following parameters were analysed. 
DEMOGRAPHIC DATA 
Among the 52 recipients, live donor transplant is 42 and cadaver 
transplant is 10.  
Among the 52 recipients, 44 were males and 8 were females. 
Predominantly male population. 
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TABLE – 2 
DONOR AGE DISTRIBUTION 
 
N MEAN 
STD. 
DEVIATION 
MINIMUM MAXIMUM 
DONOR 
AGE 
52 44.31 10.102 22 65 
 
DONOR AGE NUMBER % 
20-30 years 6 11.2 
31-40 years 11 21.1 
41-50 years 25 48.5 
50-60 years 9 17.2 
60-70 years 1 2 
TOTAL 52 100 
 
RESULTS:  (refer CHART NO.XII) 
The age of the donors ranged between 20 to 65 years in which one 
half of the donors are in the range of 41to 50 years. The mean age is 44 
years.    
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TABLE - 3 
DONOR SEX DISTRIBUTION 
DONOR SEX FREQUENCY PERCENT 
Male 15 28.8 
Female 37 71.2 
Total 52 100.0 
 
RESULTS: (refer CHART NO.1) 
Among the 52 donors 37 were females and 15 were male with 
females constituting about 2/3
rd
  of the donor population. 
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TABLE – 4 
CROSS TABULATION FOR DONOR BLOOD GROUP AND RH 
FACTOR 
DONOR BLOOD 
GROUP 
 
DONOR BLOOD 
RH TOTAL 
+VE -VE 
A N 15 3 18 
% 28.8% 5.8% 34.6% 
B N 11 0 11 
% 21.2% 0.0% 21.2% 
AB N 3 0 3 
% 5.8% 0.0% 5.8% 
O N 18 2 20 
% 34.6% 3.8% 38.5% 
TOTAL N 47 5 52 
% 90.4% 9.6% 100.0% 
 
RESULTS :( refer CHART NO.II) 
Among the donors majority carried O blood group constituting 
38% followed by A group with the least of 5% contributed by the AB 
group.  
Association of blood group with dysfunction does not carry much 
importance. 
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TABLE – 5 
DONOR RELATION 
DONOR RELATION FREQUENCY VALID PERCENT 
CADAVER 10 19.6 
MOTHER 28 52.9 
FATHER 5 9.8 
SPOUSE 6 11.8 
BROTHER 1 2.0 
SISTER 2 3.9 
TOTAL 52 100 
 
RESULTS: (refer CHART NO.III) 
Most of the donors were live donors of which majority of them 
were females.  
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TABLE – 6 
RECIPIENT AGE VS GRAFT DYSFUNCTION 
 
N MEAN 
STD. 
DEVIATION 
MINIMUM MAXIMUM 
RECIPIENT 
AGE 
52 30.44 9.595 17 56 
 
AGE FREQUENCY PERCENTAGE 
10 – 20 years 6 11.5 
20-30 years 24 46.2 
30-40 years 12 23.1 
40-50 years 8 15.4 
50-60 years 2 3.8 
Total 52 100.0 
 
RESULTS: (refer CHART NO.XII) 
Among the recipients the common age group was between 20 – 30 
years. The mean age was 30 years 
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TABLE - 7 
RECIPIENT GENDER DISTRIBUTION 
GENDER OF RECIPIENT FREQUENCY PERCENT 
MALE 44 84.6 
FEMALE 8 15.4 
TOTAL 52 100.0 
 
RESULTS :( refer CHART NO.IV) 
Among the recipients majority of them were males constituting 
around 85%. 
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TABLE - 8 
RECIPIENT BLOOD GROUP DISTRIBUTION 
RECIPIENT 
BLOOD GROUP 
BLOOD RH  
+VE -VE TOTAL 
A N 19 2 21 
% 36.5% 3.8% 40.3% 
B N 16 0 16 
% 30.8% 0.0% 30.8% 
AB N 5 0 5 
% 9.6% 0.0% 9.6% 
O N 10 0 10 
% 19.2% 0.0% 19.2% 
TOTAL N 50 2 52 
% 96.2% 3.8% 100.0% 
 
 RESULTS: (refer CHART NO.V) 
Among the recipients ‘A’ group has increased incidence of graft 
dysfunction. 
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TABLE – 9 
BIOPSY RESULTS  ANALYSIS BY BANFF ’07 UPDATE 
 
BANFF CATEGORY FREQUENCY PERCENTAGE 
NORMAL NIL NIL 
AMR 3 5.8 
BORDERLINE 6 11.5 
ACR 14 27.2 
IFTA 5 9.7 
OTHERS 21 40 
  
RECURRENCE OF          3                   5.8%  
NATIVE KIDNEY DISEASE 
   TOTAL                                      52            100% 
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TABLE - 10 
DURATION FOR REJECTION 
MONTH FREQUENCY PERCENTAGE 
0-1 MONTH 21 40.4 
1-6 MONTHS 8 15.4 
7-12 MONTHS 11 21.1 
>1 YEAR 12 23.1 
TOTAL 52 100.0 
 
Table - 11 
SUBANALYSIS OF RECIPIENTS WITH RELATION TO 
DURATION OF GRAFT DYSFUNCTION 
 
DURATION 
 
CADAVER 
LIVE 
NATIVE 
KIDNEY 
DISEASE RELATED UNRELATED 
0  - 1 month 6 (60%) 15 (41.7%) 0 (0%) 7 
1 – 6 months 2 (20%) 5 (13.9%) 1 (16.7%) - 
6 – 12 
months 
1 (10%) 8 (22.2%) 2 (33.3%) 4 
More than 1 
year 
1 (10%) 8 (22.2%) 3 (50%) 5 
Total 10 36 6 16 
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TABLE - 12 
DURATION OF REJECTION AND CATEGORIZATION OF   
RENAL BIOPSY FINDINGS USING BANFF CRITERIA 
 
MONTHS 
 
 
AB
R 
 
ACR
& 
ABR 
 
B. 
LI
NE 
 
ACR 
 
IF
TA 
 
OTHERS 
I
A 
I
B 
II
B 
II
I 
TOTAL AT
N 
CN
I 
TM
A 
C
G 
AC 
PYEL
O 
TOTAL 
0 – 1 
MONTH 
 
- 1 3 4 - 1 1 6 - 8 2 1 - - 11 
1 – 6 
MONTHS 
- - 1 3 - - - 3 2 2 - - - - 2 
7 – 12 
MONTHS 
- - 1 3 1 - - 4 1 1 2 1 - 1 5 
MORE 
THAN 1 
YEAR 
1 1 1 - 1 - - 1 2 1 - 1 1 - 3 
 
3 Recipients – Recurrence of native kidney disease   2- recurrent IgA 
nephropathy  1- Recurrent FSGS 
RESULTS: (refer CHART NO.XI)  
The major cause for graft dysfunction during the 1
st
 month of 
transplant is acute tubular necrosis followed by acute cellular rejection 
where most of the cases fall under Banff  IA . One recipient had both cell 
and antibody mediated rejection and she died on day 10 after 
transplantation. 
Another recipient who had previous native kidney disease of 
chronic glomerulonephritis with father as donor had dysfunction in the 
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14
th
 day and was diagnosed to have acute cellular rejection and was 
categorised under Banff  IA was treated with pulse dose of methyl 
prednisolone 500mg iv od for 3 days, but unfortunately he died on the 
21
st
 day. 
          During 1-6 months 3 recipients had acute cellular rejection BANFF 
IA and one recipient had borderline rejection, 2 had IFTA and 2 had acute 
tubular necrosis. 
           During 6months to 1 year the acute cellular  rejection was 
involving 4 recipients, 1 had borderline changes, 1 had IFTA while 
complications due to other causes like CNI toxicity , thrombotic 
microangiopathy and acute pyelonephritis affected 5 of the recipients. 
           After 1 year, 2 recipients had antibody mediated rejection of which 
one had combined cellular rejection too. 1 case had cellular rejection 
BANFF IB one had borderline changes and 2 has interstitial fibrosis and 
tubular atrophy. 3 cases fell into the category of others where 1 recipient 
had thrombotic microangiopathy and another with collapsing 
glomerulopathy. Three patients had recurrence of native kidney disease 1 
with recurrent FSGS at the end of 5 years of transplant and 2 other with 
recurrent IgA nephropathy one at the end of 1.5 years and other at 5 
years. 
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TABLE - 13 
CIT AND GRAFT DYSFUNCTION 
 N Mean 
Std. 
Deviation 
Median Minimum Maximum 
CIT  
(mins) 
52 68.1 54.9 50 35 240 
 
Variables Type N Mean Std. Dev P-Value 
CIT (min) 
CAD 10 156.50 77.75 
0.002 
Live 42 47.02 7.41 
 
RESULTS :( refer CHART NO.VIII) 
In view of prolonged cold ischaemic time in cadaver transplants, 
subgroup analysis was carried out between cadaver and live transplant 
recipients. 
Cadaver donors had a prolonged ischaemic time with a mean of 
156 minutes when compared to live donors mean of 47 minutes. 
The association of cold ischemic time between cadaver and live 
transplant is significant with p- value of 0.002. 
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TABLE - 14 
SERUM CREATININE AND DYSFUNCTION 
 N Mean 
Std. 
Deviation 
Median Minimum Maximum 
D1 SR CR 52 2.93 1.25 2.60 1.20 6.10 
CR NR AT 51 5.10 3.92 4.00 2 21 
 
Variables Type N Mean Std. Dev P-Value 
D1 SR CR 
CAD 10 3.40 1.19 
0.187 
Live 42 2.81 1.26 
 
Variables Type N Mean Std. Dev P-Value 
CR NR AT 
(days) 
CAD 9 12.56 3.28 
0.001 
Live 42 3.50 1.33 
 
RESULTS: (refer CHART NO.IX)  
 The comparison of day one creatinine and days taken to reach 
normal creatinine between the two groups does not show any statistical 
significance. 
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TABLE – 15 
TREATMENT DRUG DETAILS 
IMMUNOSUPP RX FREQUENCY PERCENT 
TAC/MMF 13 25.0 
CSA/AZA 33 63.5 
CSA/MMF 6 11.5 
TOTAL 52 100.0 
 
RESULTS: (refer CHART NO.VI) 
 Most of the recipients were on Cyclosporine based regimen .When 
compared to Tacrolimus, Cyclosporine has increased percentage of 
rejection rate. 
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TABLE – 16 
NEW ONSET DIABETES AFTER TRANSPLANTATION 
(NODAT) vs GRAFT DYSFUNCTION: 
NODAT FREQUENCY PERCENT 
No 48 92.3 
Yes 4 7.7 
Total 52 100.0 
 
RESULTS: 
 Out of the 52 recipients, four of them developed NODAT 
following therapy for transplantation. 
                    
 
 
 80 
 
TABLE – 17 
COMORBID STATUS vs GRAFT DYSFUNCTION: 
CO MORBID 
(HCV) 
FREQUENCY PERCENT 
No 44 84.6 
Yes 8 15.4 
Total 52 100.0 
 
RESULTS: 
               Out of 52 recipients, 8 had HCV infection prior to 
transplantation.  
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TABLE - 18 
DELAYED GRAFT FUNCTION AND DYSFUNCTION 
DGF FREQUENCY PERCENT 
No 35 67.3 
Yes 17 32.7 
Total 52 100.0 
 
RESULTS: 
         Of the 52 recipients, 32% of patients had delayed graft function. 
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SECOND BIOPSY RESULTS 
 During the follow up period 11 patients underwent second biopsy 
and the results of those patients were compared with their previous results 
and tabulated as follows: 
TABLE - 19 
HPE NO AGE/SEX 
IST BX 
DURATION 
REPORT 
IIND  BX 
DURATION 
REPORT 
715/11 26/M 6 months ACR IA 1 year IFTA 
999/11 32/M 7 months ACR IA 1.5 years Renal cortical 
necrosis 
1630/11 31/M 17
th
 day ATN 6 months ACR IA 
1774/11 45/M 3 months ACR IA 5 months ACR 
1924/11 23/M 17
th
 day ATN 6 months ATN 
196/12 27/M 11
th 
day ATN 21 days CNI toxicity 
429/12 35/M 9 days B. change 20 days ATN 
659/12 42/M 3 months ATN 4 months CNI toxicity 
1058/12 29/M 3 months IFTA 5 months CNI toxicity 
178/12 24/F 20
th
 day ACR IA 10 months CMV infection 
326/12 21/M 9 months ACR IA 1 year IFTA 
     
RESULTS: 
 Out of 11 cases, 2 cases showed progression of the disease where a 
case of acute cellular rejection turned to renal cortical necrosis and 
another case of  acute tubular necrosis progressed to acute cellular 
rejection. 
Remaining 9 cases, 7 cases regressed with treatment of which one 
had CMV infection during the follow up period and 2 cases remained the 
same despite treatment.                                             
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DISCUSSION 
A total of 52 transplant recipients with graft dysfunction who had 
regular follow up in the outpatient department of Nephrology was taken 
up for the study. Among them 10 were cadaver transplant recipients, 36 
were first degree relatives and 6 were spousal transplant recipients. 
Delayed graft function was noted in 17 recipients, 10 were cadaver 
transplants and 7 belonged to live transplant recipients. 
All the patients were started on triple immunosuppressive therapy 
consisting CNI Inhibitors, Antimetabolites with steroids. No induction 
therapy was given for cadaver or spousal transplant recipients. 
All the recipients underwent biopsy and was categorized using the 
BANFF 2007 UPDATE criteria. The results are as follows 
1. NORMAL : nil 
2. ANTIBODY MEDIATED REJECTION: 3[5.8%] 
Of these three cases one was purely antibody mediated and other 
two were with combined cell mediated rejection. 
3. BORDERLINE CHANGES : 6[11.5%] 
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4. ACUTE CELL MEDIATED REJECTION: [27.2%] 
                   IA: 10 [19.8%] 
                   IB: 2 [3.4%] 
                  II B: 1 [1.9%] 
                   III: 1 [1.9%] 
5. INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY: 
5[9.7%] 
                 MILD: 2 
               MODERATE: 2 
               SEVERE: 1 
Apart from these cases 5 other cases has been reported along with 
recurrent IgA nephropathy, acute cell mediated rejection and with 
transplant glomerulopathy. 
6. OTHER CHANGES NOT RELATED TO REJECTION :( 40.4%) 
          Acute tubular necrosis: 12 
          Cyclosporine toxicity: 4 
          Thrombotic microangiopathy: 3 
          Collapsing glomerulopathy:1 
          Acute pyelonephritis: 1 
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            Antibody mediated rejection was noted in 3 out of 52 recipients. 
Of these 3 recipients 2 had live donors and 1 had deceased donor.  All the 
three cases showed C4d positivity. The diagnosis of antibody mediated 
rejection requires presence of donor specific antibodies in the serum of 
recipient, characteristic histopathology and deposition of C4d in 
peritubular capillaries (Fig 6.4). C4d was first proposed by Feucht et al as 
a marker of humoral rejection and demonstrated correlation between 
deposition of C4d in peritubular capillaries in renal allograft biopsies and 
its  poor clinical outcome.C4d is a glycoprotein split product of C4,which 
is generated in the process of complement activation. The presence 
thioester covalent bond in C4d confers its ability to anchor tightly to 
tissues at site of complement activation. Hence C4d serves as a “foot 
print” of antibody mediated injury.C4d staining is an inexpensive, easy to 
perform and easy to interpret and specific test. But the disadvantages are 
it is not sensitive in chronic AMR and it is not useful in ABO 
incompatible transplants. AMR was seen alone in one recipient with the 
biopsy picture of margination of inflammatory cells in glomerular 
capillaries, mild mesangial hypercellularity, matrix expansion, basement 
membrane thickening with double contours (cg3) (Fig 6.3), arteriolar 
hyalinosis (ah2) fibrointimal thickening (cv2) with C4d positivity in 
peritubular capillaries under  immunofluorescence. In a study by Shamila, 
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Mauiyyedi, Marta Crespo it was found that cases with fibrinoid necrosis 
carried worse prognosis.
 [27]  
Other patient had combined AMR and ACR BANFF IB with 
severe tubulitis (t3), dense inflammatory infiltrate (i3), peritubular 
capillaritis (ptc2), interstitial fibrosis and tubular atrophy with no 
evidence of endothelitis along with C4d positivity. 
The third patient had AMR along with borderline changes 
suspicious of cell mediated rejection. One case was associated with 
transplant glomerulopathy having the features of basement membrane 
duplication (cg1), interstitial fibrosis in 30-40% of the core (ci2), 
inflammatory infiltrate (i1), arteriolar hyalinosis (ah2), fibrointimal 
thickening (cv1), with mild mesangial matrix expansion (Fig.11). 
All these patients were treated with hemodialysis, plasmapheresis 
and ATG. Despite effective measures one female patient expired on the 
10
th
 day and other 2 male patients are on maintenance hemodialysis.  It 
has been stated in a retrospective study that one year graft outcomes of 16 
patients with AMR treated with PP and IVIG and 43ACR  patients  was 
found to have a similar overall graft survival of 81% and 84% indicating 
the effectiveness of these therapies in improving the overall prognosis of 
the patient.
[28]
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Border line changes: 
 6 out of 52 patients [12%] (refer Table9) had borderline changes. 6 
recipients had borderline changes suspicious of cell mediated rejection. 
All were live transplant recipients of which 3 patients developed rejection 
in less than one month duration.  All patients had mild tubulitis (t1) with 
interstitial inflammatory cell infiltrate occupying 25% to 50% of the 
parenchymal core (i1/i2) and no endothelitis or glomerulitis and fibrin 
thrombi (Fig 5). All these patients were treated with antirejection therapy 
and responded well. One patient who had borderline changes at day 9 
after transplant underwent 2
nd
 graft biopsy which showed acute tubular 
necrosis. 
Acute cell mediated rejection:  
15 out of 52 recipients [28%] (refer table 9) had acute cellular 
rejection of which 11 were live transplants and 3 were cadaver donors. 
50% ACR occurred at the end of 1 month and 75% of them developed 
type IA ACR. (refer table 10) 
Banff type 1A ACR: 
 10 patients [19%] had acute cellular rejection of this type. Most of 
them showed moderate tubulitis with 4-6 lymphocytes per tubular cross 
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section[t2] with diffuse, dense lymphocytic infiltration in 25-50% the 
interstitium [i2,i3] (Fig 1). No vascular pathology could be made out. All 
of them underwent antirejection therapy. Five of them had 2
nd
 biopsy of 
which two progressed to IFTA, one had renal  cortical necrosis. 
Banff type 1B ACR: 
             Three patients fall under this category. These patients had 8-12 
lymphocytes per tubular cross section [t3] with dense lymphocytic 
infiltrate in more than 75% of interstitium [i3] and moderate intimal 
arteritis [v1](Fig 2). 
Banff type II B 
One patient had this type. He had severe tubulitis [t3], severe 
intimal arteritis [v2]. After antirejection therapy, he maintained normal 
graft function(Fig 3) 
Banff III: 
One patient had type III ACR. He received deceased donor kidney, 
had rejection on day 16.his biopsy showed glomerulitis [g1], multiple foci 
of interstitial infiltrate and transmural and arteritis [v3] (Fig 3 PAS, 
Trichrome stains) with one vessel showing fibrin thrombi. He had steroid 
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resistant rejection for which he was given anti thymocyte globulin, 
following which he succumbed to sepsis and died. 
Severe types (type IIB & III) of rejection were seen in cadaver 
donors probably due to prolonged cold ischaemic time. Of the 14 
recipients 10 were on cyclosporine regime and 8 on tacrolimus regimen. 
There was improvement in the serum creatinine levels during the follow 
up period in 10 recipients following methyl prednisolone therapy. Patient 
with type III ACR expired after sepsis. One patient got worsened at one 
and half years with renal cortical necrosis. Two patients turned out to 
have interstitial fibrosis and tubular atrophy with no evidence of rejection 
during the follow up period. Two patients maintained the same creatinine 
levels and biopsy findings of rejection for whom cyclosporine regimen 
was changed to tacrolimus. Intersitial fibrosis and tubular atrophy:   
          10 patients had interstitial fibrosis and tubular atrophy [22%](Fig7) 
as separate entity and along with other categories, of which 8 were live 
transplant recipients and 2 were from deceased donors. 4 patients had 
mild IFTA, 4 moderate grade and 2 severe grade. The patients with IFTA 
had significant association with HCV and CMV infection (Fig 11). 
Patients with moderate to severe IFTA progressed to chronic graft 
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dysfunction and they were maintained on therapy with Aspirin, Enalapril 
and Atorvastatin. 
Others: 
          Acute tubular necrosis was observed in 10 out of 52 recipients. 
Among these 10 recipients 8 had ATN within the 1
st
 month during 
the immediate post operative period.2 recipients developed during the 
follow up period. All these recipients were subjected to biopsy after 
ruling out other causes. During the follow up period 2 patients died at the 
end of one month and one year due to fungal pneumonia. Rest of the 
recipients recovers completely with normal creatinine levels. 
          Three patients had thrombotic microangiopathy pattern seen in 
variety of diseases like hemolytic uraemic syndrome, thrombotic 
thrombocytopenic purpura, postpartum renal failure, drug therapy by 
cyclosporine and tacrolimus, antiphospholipid antibody syndrome and 
humoral allograft rejection. Histologically the glomeruli show thickened 
capillary walls, amorphous sub endothelial deposits leading on to 
“bloodless glomeruli’’. Glomerular thrombi are seen. (fig 9). All the three 
TMA were presumed to due to calcineurin inhibitors. 2 were on 
cyclosporine therapy, one under tacrolimus regimen. All these recipients 
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had denovo TMA. Calcineurin based immunosuppression was stopped in 
those patients. Despite stopping the offending drug, one patient died and 
other two improved. 
          CNI toxicity was seen in 4 patients of whom 3 were on 
cyclosporine regime and one on tacrolimus.  3 patients had chronic CNI 
toxicity and one patient had acute CNI toxicity. The features suggestive 
of acute toxicity include acute arteriopathy of glomerular capillaries, 
isometric vacuolization (fig.8) and thrombotic microangiopathy. The 
chronic features which were suggestive of toxicity include interstial 
fibrosis and tubular atrophy, arteriolar hyalinosis, glomerulosclerosis and 
tubular microcalicfication. The presence of isometric vacuolization 
identified by the presence of small uniform sized vacuoles in the 
cytoplasm of tubular epithelial cells. This usually involves the proximal 
tubules especially the straight portion. 
[29] 
In more than 1000 diagnostic 
biopsies done isometric vacuolization was seen in 40% of cases during 
the first 2 weeks , 30% at 6 months , 18% at 1 year and 8% at three years 
.
[30] 
Other two findings in favour of CNI toxicity include giant 
mitochondria and dystrophic micro calcification.  
All of them underwent frequent drug level monitoring and dosage 
was adjusted according to levels. All these recipients maintained stable 
creatinine levels after dose reduction. 
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Recurrence of native kidney disease was noted in 3 cases of which 
2 were recurrent IgA nephropathy and one had recurrence of FSGS. The 
recurrence of IgA nephropathy has been reported  as 37% to 60% (refer 
table 1) .
[31]
The frequency of recurrence increases with time as IgA  
negative biopsies averaged 15 months and IgA positive biopsies averaged 
46 months of post transplantation.
[32]
 This indicates that with increased 
graft survival time recurrence of glomerular IgA deposits will be more 
common. In our study, the recurrence of IgA nephropathy occurred after 
a duration of 5 years and 18 months. Both the patients presented with 
nephrotic proteinuria. 
[33] 
In this study also the serum creatinine returned 
to normal and the graft survival remained fairly better at the end of one 
year.    
Recurrence of FSGS occurred in 30-50% of graft and is associated  
with increased graft failure rate.
[34]  
Contrary to IgA , recurrence of FSGS 
can occur within days to months after transplant.
  
Among the FSGS 
variants, Collapsing type frequently recurs. 
[35] 
  The recurrence is mainly 
due to rapid progression of the primary disease. The rate of recurrence 
increases more in case of live donors where as in our study it occurred in 
cadaver donor. Aggressive plasmapheresis will lead to long lasting 
remission in these patients.  In our study, a case of collapsing 
glomerulopathy was reported in a non HIV patient with spousal donor 
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after four and half years of transplant. The microscopic findings included 
2 globally sclerotic glomeruli out of 9 and mesangiolysis with podocyte 
hyperplasia with complete collapse of the glomerular tuft in 3 glomeruli 
with remaining normal glomeruli (Fig.10). There was moderate arteriolar 
hyalinosis.  The patient was under maintenance hemodialysis for one year 
and died at the end of five years after transplant.  
Acute pyelonephritis occurred as a complication of renal 
transplantation in one of our female recipients following cadaver 
transplant in duration of 7 months. This accounts for 1.6% of transplant 
patients and females account for 93% of cases.
[36]
 It usually present as 
acute renal failure and cause graft loss and commonly one year or more 
after transplantation. 80% is mainly due to E.coli organisms. 
Histologically identified by the presence of neutrophils between tubular 
epithelial cells and in the adjacent edematous interstitium.  
Univariate and multivariate analysis were done for all the 
parameters and the results are analysed below: 
1. The association of graft function with donor age was analysed. The 
mean age was 44 years.  The study done by Jhon swanson et al & 
Fernando G cosio et al states that increased donor age correlates 
with reduced graft survival. Our study also showed around  70 % 
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of donors were in the age group  of  more than 40 years which 
correlates with decreased graft survival.
[37]
 
2. Most of the donors in this study were female, particularly live 
donor transplant. Donor gender was analyzed with graft function. 
The study done by Neugarten J et all & Martin Zeier et al 
confirms that longevity of graft survival is affected when female 
kidneys were transplanted to male recipients
 [38]
. The gender effect 
is more in case of young donors compared to older donors. The 
proposed hypothesis is nephron dosing.
[39]
 
3. The donor relation was analysed. It was found that majority of our 
dysfunction patients were live donors and it is mainly due to the 
increased number of live donors nearly two thirds of total 
transplants.  
4. Recipient age was studied. In this study 70% of them were young 
recipients of age less than 40 years. 
5. The increased association of male recipients with graft dysfunction 
was significant due to the fact that most of them received graft 
from female donors. A study by Vereerstraeten P et al showed 
that inferior graft outcome when kidneys of female donors were 
transplanted into male recipients and also showed significantly 
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higher incidence of rejection in male recipients who received 
organs from female donors. 
[40]
 
6. A study done by Stefan gunthertullius et al compared cold 
ischaemia time and donor age with  graft  dysfunction and 
confirmed that prolonged ischaemic time of > 120 minutes affects 
the graft survival significantly in case of live donor transplants. 
Cold ischemic time varies between cadaver and live donor 
recipients due to transportation of organs from varied places .
[41]
 
There is a significant association in the cold ischaemic time of 
cadaver transplant (mean time-149 minutes) and live transplants 
(47 minutes) with p value of 0.002 (refer table 13).   
7. Number of  days after transplantation  required to reach the normal 
creatinine is an important determinant of long term graft 
function.The mean days for cadaver transplant was 12 days and for 
live 3 days with a significant p-value of 0.001.  This was confirmed 
by the study by Magaligiral-Classe et al, showed that delayed 
graft function of more than 8 days to reach the baseline creatinine 
of 1.2 is associated with increased risk of graft dysfunction.
[42]
 
(refer table 14). 
8. Acute antibody mediated rejection is associated with poor graft 
outcome. Three of our patient [5.8%] had antibody mediated 
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rejection.One patient who underwent deceased donor transplant 
had acute AMR at day 10.She had delayed graft function and 
dialysis dependency. Her biopsy showed diffuse glomerulitis with 
fibrin thrombi and peritubular capillaritis as well as intimal 
arteritis. C4d was intense positive. Despite antirejection therapy 
and plasmapheresis, she died. The other two, who underwent live 
related transplant developed chronic AMR at 4-5 years after 
transplant has slow deterioration in graft function. Studies by 
Halloran PF, Wadgymar et al  insist that outcome of AMR 
improves when treated with aggressive immunosuppressive 
therapy. 
[43]
 
9. In a study by Feucht et al describing the importance of staining 
pattern of C4d with 1year graft survival stating 57%, 63% and 90% 
in diffuse, focal and negative staining respectively. 
[44]
As per our 
study all the three cases had a diffuse C4d (Fig.6.4) staining and 2 
cases had a graft survival of  less than one year and one recipient 
had survival of 4 years which states that diffuse staining is  
associated with poor graft survival. 
10. 30% patients had an episode of acute cellular rejection, 50% of the 
episode occurred within the first month, majority [75%] of them 
were of Banff type 1A. 
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11. Only two patients has severe forms of rejection [one-type IIB; one- 
III]. Both these patients received deceased donor graft. Patient with 
type III ACR died of sepsis after treatment with anti rejection 
therapy. 
12. CMV infection was seen in a patient after 10 months of 
transplantation in the second biopsy, who had acute rejection 
during 20 days posttransplant. She was treated and now she is 
under normal follow up (Fig.12). 
13. 8 patients with HCV infection underwent live related transplant. 
Two of them had cellular rejection of low severity. They had 
increased incidence of interstitial fibrosis and tubular atrophy, 
which may be probably due to increased NODAT &CMV.   
14. Majority of the rejections fell under BANFF IA among the 
categories in BANFF criteria. This type had a better graft survival 
than severe types of acute rejection like IIB and III. 
15. Delayed graft function [requirement of dialytic support within one 
week of transplantation] occurred in 20% patients, which is a 
crtitical determinant of longterm graft function. 
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SUMMARY 
In our study, 52 patients with renal dysfunction were selected and 
various parameters were analysed and the observations are summarized 
below: 
 42 had live donor transplant and 10 had deceased donors.  
 Of the recipients 44 were male and 8 were females.  
 The mean age of the donors was 44 years with two thirds of them 
being females and majority of them were live donors.  
 ‘O’ blood group was the commonest blood group among the 
donors. 
 The mean age for recipients was 30 years with males constituting 
85% and ‘A’blood group being common among them. 
 Majority of the donors (40%) developed graft dysfunction during 
the first month of transplant of which 60% was constituted by 
cadaver donors due to prolonged cold ischaemic time of cadaver 
donors to live donors with a significant p- value of 0.002. 
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 Among 52 recipients, one had ABR, 2 had combined ACR and 
ABR, 6 had borderline changes, 14 had ACR, 5 had IFTA and 21 
belonged to the category of others.  
 During the follow up period ACR carried a better outcome 
compared to ABR 
 Most of the recipients were on Cyclosporine based regimen. 
 8 had HCV infection during the course of their transplantation and 
4 developed NODAT after transplant. 
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                                                                        CONCLUSION 
Based on this study on clinicopathological study of renal allograft 
dysfunction the following findings were noted: 
 
* Donor age has significant impact on long term graft survival; 
younger the donor better the outcome. 
 
* With female donors the graft dysfunction is more, may be due to 
different in antigenicity and smaller renal mass. 
 
* Live related renal transplantation had better outcomes than 
deceased donor transplants, reasons being better HLA match, 
reduced cold ischemic time and low incidence of  delayed graft 
function. 
 
* Delayed graft function occurred in 20% patients, which is a 
significant impact on long term graft function survival. 90% 
deceased donor recipients have delayed graft function. 
 
* Prolonged Cold ischaemic time is an important cause delayed graft 
function. There is a significant p value of 0.002 between live and 
deceased donor transplant. [47 minutes versus 157 minutes].  
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* Antibody mediated rejection occurred in 6% of patients. None of 
them had hyper acute rejection, which implies better method of 
cross match in our set up.  
 
* Acute cellular rejection occurred in 30% patients which is 
relatively high when compared to western standards of 10-15%, 
where all patients undergo anti induction therapy to prevent early 
rejection.  
 
* 50% acute cellular rejection occurred in less than 1 month of 
transplantation, hence there is a need for anti induction therapy to 
prevent early rejection. 
 
* 75% of cellular rejections were of Banff type 1 A variant, which 
responded very well to treatment. 
 
* 20% our patient had interstial fibrosis and tubular atrophy, which is 
a important cause of late allograft failure. 
 
‘EVERY DONOR KIDNEY IS A BOON TO THE RECIPIENT; HENCE IT 
MUST BE  EFFECTIVELY  HANDLED TO PROLONG THE LIFE OF 
THE GRAFT AND  THEREBY PROVIDE A GREAT TREASURE TO 
THE POOR RECIPIENT’. 
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ANNEXURE – I 
EVALUATION FORM FOR PATIENTS WITH RENAL 
ALLOGRAFT DYSFUNCTION 
 
NAME OF THE RECIPIENT: 
AGE/SEX: 
BLOOD GROUP: 
DONOR STATUS: LIVE/ CADAVER 
IF LIVE : RELATED/ UNRELATED : 
BLOOD GROUP OF THE DONOR: 
HLA MATCHING DONE/ NOT: 
DATE OF TRANSPLANTATION: 
TIME OF DEVELOPMENT OF DYSFUNCTION : 
SERUM CREATININE LEVELS: 
COLD ISCHAEMIC TIME: 
DELAYED GRAFT FUNCTION: YES/ NO 
COMORBID STATUS: HBV/ HCV/DM/HT 
NODAT +/- 
RENAL BIOPSY DETAILS: 
NORMAL 
ANTIBODY MEDIATED REJECTION 
BORDERLINE CHANGES 
ACUTE CELLULAR REJECTION: IA /IB/IIA/IIB/III 
IFTA 
OTHERS (SPECIFY) : 
FOLLOW UP SERUM CREATININE : 
FOLLOW UP BIOPSY (IF AVAILABLE): 
KEY TO MASTER CHART 
ABR: Antibody mediated rejection  
ACR : Acute cellular rejection 
ATN: Acute tubular necrosis  
CAD: Cadaver 
CGN : Chronic glomerulonephritis  
Cit : Cold ischaemic time 
CMV: Cytomegalovirus 
CNI : Calcineurin inhibitor 
DGF: Delayed graft function 
GGS: Global glomerulosclerosis 
HCV: Hepatitis C virus 
IFTA: Interstitial fibrosis and tubular atrophy 
NKD: Native kidney disease 
NODAT: New onset diabetes after transplant 
PP+ IST: Plasmapheresis and immunosuppression therapy 
  
 FIG 1 : BANFF IA 
Lymphocytic infiltrate in 30–40% of core (i2), moderate  
tubulitis (t2), no arteritis 
   Fig 1.1  H&E                                                  Fig  1.2   PAS 
             
 
FIG 2 : BANFF IB 
Lymphocytic infiltrate throughout the cortical core (i2) 
Tubulitis with 8−12 lymphocytes per tubular cross section (t3) 
           Fig 2.1   H& E                                              Fig 2.2  PAS 
           
 FIG 3 : BANFF II B 
   Fig 3.1   H& E             Fig 3.2      PAS 
Severe tubulitis (t3),   Severe arteritis (v2) 
              
          
FIG 3 :   BANFF III 
Moderate lymphocytic interstitial infiltrate (i2), Moderate  
tubulitis (t2), transmural arteritis (v3) 
         Fig 3.1   H&E                                               Fig 3.2   H&E 
               
 
 Fig 4 : BANFF III 
Arteriolar hyalinosis with Fibrin thrombi 
      Fig 4.1  PAS              Fig.4.2 TRICHROME 
              
    
FIG 5 : BORDERLINE CHANGES 
Inflammatory infiltrate <25% of core, mild Tubulitis 
Fig 5.1   H&E                     Fig 5.2  PAS 
               
   
                                                                                      
 FIG 6: ANTIBODY MEDIATED REJECTION 
           Fig 6.1 H&E           Fig 6.2   PAS 
                 
Glomeruli with minimal inflammation         Glomeruli with mesangial matrix  
expansion  
 
Fig 6.3  METHANAMINE SILVER  Fig 6.4    C4D STAINING  
Basement membrane thickened with   IN PERITUBULAR  
double countours     CAPILLARIES  
                
 
                                  
 
 
 
 FIG 7: INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY 
      Fig 7.1 H&E                       Fig 7.2  TRICHROME 
                
 
FIG 8: ACUTE TUBULAR INJURY    FIG 9: THROMBOTIC 
       MICROANGIOPATHY 
          PAS STAIN      H&E  STAIN 
 
                        
Isometric vacuolisation     Fragmented  RBC  in 
of tubular                             glomerulus   
epithelial cells    
 
 
 Fig 10:  COLLAPSING GLOMERULOPATHY 
COLLAPSED TUFT OF GLOMERULI 
       Fig 10.1   H&E                                         Fig 10.2   PAS 
                   
 
FIG 11: TRANSPLANT    
GLOMERULOPATHY                FIG 12: VIRAL INFECTION 
PAS –METHANAMINE SILVER           CMV INCLUSION 
Glomerular basement membrane  
duplication  
                  
                                                 CHARTS 
1: DONOR SEX vs GRAFT DYSFUNCTION 
 
 
 
II. DONOR BLOOD GROUP vs DYSFUNCTION 
 
 
 
 III. DONOR RELATION vs DYSFUNCTION 
 
 
 
IV. GENDER OF RECIPIENT vs DYSFUNCTION 
 
 
 
 V: RECIPIENT BLOOD GROUP AND DYSFUNCTION 
 
 
 
VI: THERAPY AND DYSFUNCTION 
 
 
 
 VII. COMPARISON OF DONOR TYPE WITH GENDER OF 
RECIPIENT 
 
 
VIII: COMPARISON OF MEAN COLD ISCHAEMIC TIME (CIT) 
BETWEEN CADAVER AND LIVE DONOR TRANSPLANTS 
 
 
 IX. COMPARISON OF MEAN DAY 1 CREATININE BETWEEN 
LIVE AND CADAVER DONOR TRANSPLANTS 
 
 
X.COMPARISON OF DAYS TAKEN TO REACH NORMAL 
CREATININE BETWEEN LIVE AND CADAVER DONOR 
TRANSPLANTS 
 
 
 XI. DYSFUNCTION AND BANFF CATEGORIES 
 
 
XII. MEAN AGE OF DONOR AND RECIPIENT VDYSFUNCTION 
 
 
CR NR 
AT DIS CR
COMORBI
D
TYPE RELN AGE SEX BLD GR HCV NODAT ABR BORDERLINE ACR IFTA OTHERS
1 715/11 26 M NA 6 mon 4.8 12 1.3 yes 240 TAC/MMF A+ CAD CAD 26 M A+ no YES _ IA _ III _ NEG 1 year IFTA + cr 2 Maint
2 975/11 24 M NA 7 mon 2.4 3 0.9 no 45 CSA/AZA A+ LIVE SPOUSE 22 F O+ yes _ __ _ _ _ _ CNI TOX NEG _ _ N
3 999/11 32 M NA 21st day 1.8 2 1 no 50 CSA/AZA B+ LIVE MOTHER 50 F O+ no YES _ _ IA _ _ NEG 1.5 year cor 
necrosis IST
4 1000/11 29 M CGN-CKD 14th day 2.8 4 1.6 yes 60 CSA/AZA B+ LIVE FATHER 60 M B+ no _ _ _ _ _ _ TMA NEG _ _ DIED 3 WKS 
5 1582/11 18 F NA 1 year 3.4 4 1 no 55 CSA/AZA A+ LIVE MOTHER 45 F A- yes _ _ _ __ _ I NEG _ _
6 1630/11 31 M NA 17th day 4 11 1.7 yes 35 TAC/MMF A- CAD CAD 45 F A- no _ __ _ _ _ _ ATN NEG 6months ACR IA Died 13m
7 1774/11 45 M NA 3 Months 4.8 5 1.5 no 60 TAC/MMF A+ LIVE SPOUSE 40 F A+ no _ __ __ IA _ _ _ NEG 5 months ACR IA maint rx
8 1823/11 29 M NA 4.5 Yrs 3.8 4 1 no 45 CSA/AZA A+ LIVE SPOUSE 24 F A+ no _ _ _ _ _ _ Collap glom NEG died at 5 yrs
9 1924/11 23 M NA 17th day 2.5 2 0.8 no 45 CSA/AZA B+ LIVE MOTHER 50 F B+ yes _ _ _ _ _ _ ATN NEG 6months ATI cr 1.8
10 1972/11 29 M NA 15th day 2.4 3 1.2 no 50 CSA/AZA O+ LIVE MOTHER 55 M O+ yes _ _ _ _ _ _ ATN NEG HCV + DIED 1 
MONTH
11 1973/11 20 M NA 10th day 1.4 2 0.8 no 45 CSA/AZA O+ LIVE MOTHER 42 F O+ no YES _ _ _ _ _ CNI TOX NEG N
12 2050/11 17 M NA 4 months 4.8 2 1.2 no 55 CSA/AZA O+ LIVE MOTHER 40 F O+ no _ _ _ _ _ _ ATN NEG N
13 2076/11 27 M NA 3.5 years 3.8 3 0.8 no 50 CSA/AZA A+ LIVE FATHER 60 M A+ no YES _ PRESENT _ _ II TX GLOM NEG maint rx
14 196/12 27 M NA 11 days 4.2 3 1 yes 50 CSA/AZA B+ LIVE MOTHER 47 F B+ no _ _ _ _ _ _ ATN NEG 21 days CNI TOX CR2.5 N
15 249/12 18 M PUV 11 months 2.3 4 1 no 50 CSA/AZA A+ LIVE BROTHER 36 M A- no _ _ _ _ _ II NEG N
16 360/12 19 M NA 6 months 4.7 3 1.2 no 35 CSA/AZA A+ LIVE MOTHER 35 F A+ yes _ _ _ _ _ III NEG N
17 428/12 33 M IgA Nep 4 Years 3.3 2 1.1 no 35 CSA/AZA B+ LIVE MOTHER 48 F O+ no _ + _ IB _ _ _ POSITIV
E
IST+PP
18 429/12 35 M NA 9 days 6.1 5 2.4 yes 40 CSA/AZA A- LIVE MOTHER 45 F O+ no _ _ PRESENT _ _ _ _ NEG 20 days ATN DIED 1YR
19 464/12 32 M NA 12 days 1.6 3 2 yes 50 CSA/AZA B+ LIVE MOTHER 49 F B+ yes _ _ PRESENT _ _ _ _ NEG N
20 476/12 25 M NA 8 months 2.8 3 1.4 no 45 CSA/AZA O+ LIVE MOTHER 40 F O+ no _ _ PRESENT _ _ _ _ NEG N
21 964/12 45 M NA 1 year 4.6 3 1.2 no 50 CSA/AZA A+ LIVE SPOUSE 40 F A+ no _ _ _ IB __ _ _ NEG N
22 1378/12 33 F NA 7 days 4.4 3 1.7 no 35 CSA/MMF O+ LIVE SISTER 48 F O+ no _ _ _ _ _ _ cni toxicity NEG N
23 2000/12 24 M NA 14 days 5.2 4 1.8 no 60 TAC/MMF A+ LIVE MOTHER 41 F O+ no _ _ _ _ _ _ ATN NEG N
24 4846/11 42 M IgA Nep 1.5 yrs 2.4 4 1.1 no 55 CSA/MMF B+ LIVE FATHER 59 M B+ no _ _ _ _ _ I REC IGA NEG IgA 
+
N
25 659/12 42 M Renal A ste 3 Months 2.1 3 1.4 no 45 CSA/AZA B+ LIVE MOTHER 58 F B+ no _ _ _ _ _ _ ATI NEG 4 months CNI TOX N
D1 SR 
CR
days
SNO BX NO AGE SEX NKD POST TX FOLLOW UP2ND BIOPSY DETAILSC4DDGF cit (min) BLD GR
IMMUNO 
supp Rx
DONOR BIOPSY DETAILS
26 825/12 29 M NA 8 Months 3.2 5 1.1 no 45 CSA/MMF AB+ LIVE FATHER 55 M A+ yes _ _ __ _ _ _ _ NEG 1 year ATN N
27 979/12 21 M NA 2 Months 3.6 5 0.9 no 50 CSA/MMF AB+ LIVE MOTHER 42 F AB+ no _ _ _ IA _ _ _ NEG N
28 2300/12 22 F ADPKD 12 days 1.6 4 1.2 no 45 CSA/AZA A+ LIVE MOTHER 45 F A+ no _ _ _ IA _ _ _ NEG N
29 1142/12 25 F ch IgA Nep 10months 1.9 3 1 no 60 CSA/MMF B+ LIVE MOTHER 45 F B+ no _ _ _ IB _ _ _ NEG N
30 1792/12 23 M NA 1 day 1.6 4 1.2 no 35 CSA/AZA A+ LIVE MOTHER 52 F O + no _ _ _ _ _ _ ATN NEG N
31 1058/12 29 M NA 3 Months 2.1 12 1.7 yes 240 TAC/MMF A+ CAD CAD 49 M A+ no _ _ _ _ _ II GGS AH-S NEG CNI N
32 2346/12 35 M NA 2.5 yrs 1.7 4 1 no 50 CSA/MMF B+ LIVE SISTER 33 F O+ no _ _ _ _ _ I _ NEG maint rx
33 178/12 24 F Dypl/PUJ 20days 2.6 3 1.2 yes 45 CSA/AZA O+ LIVE MOTHER 45 F O+ no _ _ _ IA _ _ _ NEG 10 
Months CMV N
34 326/12 21 M VUR 9 months 2.4 4 1.4 no 50 CSA/AZA A+ LIVE MOTHER 45 F A+ no _ _ _ IA _ _ _ NEG 1.5 year IFTA II maint rx
35 343/12 37 M NA 8 months 4.1 3 1.2 no 50 CSA/AZA A+ LIVE MOTHER 50 F O- no _ _ _ IA _ _ _ NEG N
36 125/12 29 M NA 4 Years 2.8 3 1.5 no 50 CSA/AZA AB+ LIVE MOTHER 45 F A+ no _ + _ _ _ _ _ POSITIV
E
DIED
37 1500/11 32 M NA 16 days 2.6 13 2.5 yes 120 TAC/MMF A+ CAD CAD 44 M A+ no _ _ _ III _ _ _ NEG N
38 361/12 21 M NA 4 months 2.4 4 2 no 35 CSA/AZA B+ LIVE MOTHER 50 F B + no _ _ PRESENT _ _ _ _ NEG N
39 824/12 36 M NA 7 days 1.9 3 1.1 no 40 CSA/AZA B+ LIVE MOTHER 50 F O + no _ _ _ IA _ _ _ NEG N
40 516/12 42 M DM NEPH 6 days 3.2 11 2.4 yes 80 TAC/MMF AB+ CAD CAD 24 M AB+ no _ _ _ IIB _ _ _ NEG N
41 2433/12 23 M FSGS 5 years 2.8 11 0.8 yes 60 CSA/AZA B+ CAD CAD 35 F B no _ _ _ _ _ _ FSGS NEG N
42 2752/12 26 M FSGS 9 days 1.7 4 1.2 no 40 CSA/AZA B+ LIVE FATHER 55 M B+ no _ _ PRESENT _ _ _ _ NEG
CNI 
TOXICIT
Y
CR1.4
43 2779/12 56 F NA 7months 2.1 12 1.1 yes 190 TAC/MMF A+ CAD CAD 30 M A+ no _ _ _ _ _ _ ac pyelonep NEG N
44 3048/12 28 M NA 9 days 2.1 3 1.5 no 55 CSA/AZA A+ LIVE MOTHER 58 F A+ no _ _ _ _ _ _ ATN NEG N
45 2996/12 21 F IgA Nep 5 years 1.3 3 1.4 yes 35 CSA/AZA B+ LIVE MOTHER 36 F B+ no _ _ _ _ _ I IgA neph NEG N
46 2263/12 36 F NA 10 days 5.8 no 
normal exp yes 180 TAC/MMF O+ CAD CAD 32 M O+ no _ + present _ _ _ _
POSITIV
E
PP+IST died
47 2789/12 33 M NA 7 months 1.9 2 1.2 no 40 CSA/AZA O+ LIVE MOTHER 59 F O+ yes _ _ _ IA _ II NEG N
48 2359/12 46 M IgA Nep 4 days 3 10 1.1 yes 240 TAC/MMF A+ CAD CAD 28 M A+ no _ _ _ _ _ _ ATN NEG IFTA maint rx
49 3128/12 44 m IgA Nep 11 months 1.3 3 0.9 no 40 TAC/MMF 0+ LIVE SPOUSE 41 F 0+ no - cni toxicity NEG N
50 3416/12                                                                                                                      52 M DM NEPH 21 DAY 3.6 21 3.4 yes 180 TAC/MMF AB+ CAD CAD 65 M AB+ no - - ATN NEG N
51 3632/12 50 M DM NEPH 2 YRS 1.3 10 1.4 no 55 TAC/MMF 0+ LIVE SPOUSE 42 F O+ no - TMA NEG Dialysis
52 2872/12 17 M NA 11 months 1.2 3 0.8 yes 45 CSA/AZA B+ LIVE  44 F O+ no _ TMA NEG csato tac
ABSTRACT 
INTRODUCTION:  
                   Chronic kidney disease forms an emerging worldwide health 
problem and renal transplantation is the best cure available at this time to extend 
the life of the patient. To improve the survival of graft identifying the etiology 
and pathology of graft dysfunction becomes most essential. BANFF criteria 
helps in standardisation of renal allograft biopsy interpretation and acts as a 
guide to therapy and thereby minimizes intra and inter observer variations in 
interpretation of graft biopsies.  
 AIM OF THE  STUDY : 
                       To analyse the clinicopathological spectrum of renal allograft 
dysfunction in a tertiary care hospital over a period of  3 years. 52 patients 
developed graft dysfunction for whom parameters like age, sex, type  of  donor, 
cold ischaemic time, delayed graft dysfunction were studied and 
histopathological findings were categorized using BANFF 2007, Update 
criteria.  
OBSERVATION AND RESULTS:  
                 42 had live donor transplant and 10 had deceased donors. Of the 
recipients 44 were male and 8 were females. The mean age of the donors was 44 
years with two thirds of them being females and majority of them were live 
donors. The mean age for recipients was 30 years with males constituting 
85%.Majority of the donors developed graft dysfunction during the first month 
of transplant of which 60% was constituted by cadaver donors .Among 52 
recipients, one had ABR, 2 had combined ACR and ABR, 6 had borderline 
changes, 14 had ACR, 5 had IFTA and 21 belonged to the category of others. 
During the follow up period ACR carried a better outcome compared to ABR. 
Most of the recipients were on Cyclosporine based regimen.8 had HCV 
infection during the course of their transplantation and 4 developed NODAT 
after transplant. 
CONCLUSION: 
            These  parameters had a significant impact on graft survival. Acute 
cellular rejection (BANFF IA) had a better outcome when compared with 
antibody mediated rejection. Hence live donor transplant, better HLA match, 
preinduction therapy ,  prompt and precise histological diagnosis becomes 
essential to prevent early graft loss and thereby increase the survival of the 
recipient. 
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